CanSino: The DTcP-Hib-MCV4 combination vaccine initiates Phase I clinical trials and completes the enrollment of the first subject.

CanSino announcement, the company's adsorption-free cell-free combined vaccine for tetanus, diphtheria, pertussis, Flu B, Haemophilus influenzae type b, and meningococcal serogroups ACYW135 has officially started Phase I clinical trials recently, and the first subject has been enrolled.